CO22 Health-Related Quality of Life from a Phase 4 Global Clinical Study to Evaluate Discontinuation and Rechallenge of Pexidartinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) Previously Treated with Pexidartinib
Desai, J., Wagner, AJ, Carrasco, Garcia I., Cesari, M., Gordon, M., Lin, CC, Papai, Z., Ryan, CW, Tap, WD, Trent, JC, Gelderblom, H., Grimison, P., López, Pousa A., Tine, Van, Dai, D., Rubinacci, M., Tecson, K., Wooddell, M., Stacchiotti, S.
Published in Value in health (01.06.2024)
Published in Value in health (01.06.2024)
Get full text
Journal Article
58MO Evaluation of three pexidartinib doses in a global phase IV clinical study of patients with tenosynovial giant cell tumor (TGCT) who chose to continue treatment
Stacchiotti, S., Wagner, A.J., Garcia, I.C. Carrasco, Cesari, M., Gordon, M., Lin, C-C., Papai, Z., Ryan, C.W., Tap, W.D., Trent, J.C., Gelderblom, H., Grimison, P., Pousa, A. Lopez, Van Tine, B.A., Rubinacci, M., Tecson, K., Wooddell, M., Desai, J.
Published in ESMO open (01.03.2024)
Published in ESMO open (01.03.2024)
Get full text
Journal Article